platoseedplatoseed
Nomic is doing for proteins what Illumina has done for DNA
Nomic is doing for protein profiling, what Illumina did for DNA sequencing. Our core technology, the nELISA, is a next-gen immunoassay platform that transforms the ELISA into a high-throughput, high-content, and high-versatility tool. Today we developed the nELISA for high-throughput drug discovery scientists, enabling them profile 100s of proteins at 10x higher throughput and 10x lower cost compared to existing solutions. We're offering the nELISA through early access programs to HTS groups in top pharmas as well as pioneering biotechs in the space. Our goal is to create a ubiquitous technology that consolidates the broad range of legacy immunoassay toolkits that scientists use today with a single platform that can carry the science end-to-end, from discovery all the way to the clinic. We're a team of engineers, biologists, and highly-skilled lab operators that are looking to grow quickly to keep up with customer demand but also to continue developing our core technology, scale our multiplexing/throughput, and build our software stack. We're hiring on a number of positions including engineering, software, biology, and ops. Come talk to us!
Nomic Bio provides a scalable proteomics platform that offers affordable, high-fidelity protein profiling and end-to-end proteomics services. It emphasizes absolute quantification across a broad protein library and rapid, high-throughput turnaround to democratize proteomics for research and translational work.
Omni 1000 is a proteomics platform accompanied by core and flex service options. It offers a library of ~1000 informative proteins with absolute quantification, enabling targeted discovery with ~300-protein panels (Core) or custom marker selections (Flex). The platform uses nELISA technology (re-engineered sandwich immunoassay with DNA as a programmable linker) to deliver true multiplexing at scale, high sensitivity and specificity, and data in days. Services are designed as an end-to-end solution with rapid turnaround (as fast as one week) and an emphasis on affordability for large-scale studies, including automation-backed analysis and expert support.
Who it’s for: Researchers and institutions engaged in proteomics, biomarker discovery, translational and drug discovery programs seeking high-throughput, absolute-quantified protein panels with flexible customization.
Public announcements of partnerships, grants, and funding milestones; multiple news items highlighting product launches and expansion, indicating active growth and commercial traction.
Formerly “nplex biosciences” · why startups rename →
AI-designed Affinity Reagents
We use AI to design antibodies for intractable diseases
